Table 2.

Summary of randomised trials of neoadjuvant chemoradiotherapy in esophageal cancer

Trial/author	Year	No. of patients	Chemotherapy (cycles)	Radiotherapy	Histology
Nygaard	1983	78	Cisplatin/bleomycin(2), sequential	35Gy/(1.75Gy/#)/4 weeks	Squamous
Apinop	1986	69	Cisplatin/5-FU(2), concurrent	40Gy/(2Gy/#)/4 weeks	Squamous
Le Prise	1988	86	Cisplatin/5-FU(2), sequential	20Gy/10#/12 days	Squamous
Urba	1989	100	Cisplatin/5FU/vinblastine(2), concurrent	45Gy/(1.5Gy/#)/3 weeks	Squamous/adeno
Bosset	1989	293	Cisplatin (2), sequential	37Gy/(3.7Gy/#)/2 weeks	Squamous
Walsh	1990	61	Cisplatin/5FU(2), concurrent	40Gy/15#/3 weeks	Squamous
Walsh	1990	113	Cisplatin/5FU(2), concurrent	40Gy/15#/3 weeks	Adeno
Burmeister	1994	256	Cisplatin/5FU(1), concurrent	35Gy/15#/3 weeks	Squamous/adeno
Tepper	1997	56	Cisplatin/5FU(2), concurrent	50.4Gy/(1.8Gy/#)/5.6 weeks	Squamous/adeno
Lv	1997	160	Cisplatin/paclitaxel(2), concurrent	40Gy/(2Gy/#)/4 weeks	Squamous
Lee	1999	101	Cisplatin/5FU(2), concurrent	45.6Gy/(1.2Gy/#)/28 days	Squamous
Mariette	2000	195	Cisplatin/5FU(2), concurrent	45Gy/25#/5 weeks	Squamous/adeno
Van der Gaast	2004	364	Carboplatin/paclitaxel(5), concurrent	41.4Gy/(1.8Gy/#)/4.6 weeks	Squamous/adeno

Adapted with permission from Sjoquist KM et al.: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-92